ArticleNature medicine2020
A single-cell landscape of high-grade serous ovarian cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 333 papers.
0numbers the graph read from it
0cells of the map it votes in
333citing papers in PubMed
27.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
333 citing papers in PubMed, 506 citations in OpenAlex.
- Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Trial
- CellSearch-based isolation of circulating tumor cells from ascitic fluid enables molecular characterization of ovarian cancer.The journal of liquid biopsy · 2026Article
- A membrane-penetrating modified ascites-derived peptide, TAT-CPAP1, sensitizes TP53 wild-type ovarian cancer cells to platinum-based therapy through targeting the NOLC1-MDM2/MDM4 axis.Translational oncology · 2026Article
- Characterizing intra- and intertumor heterogeneity in ovarian high-grade serous carcinoma subtypes using single-cell and spatial transcriptomics.Genome research · 2026Article
- Standardized Upstream Processing of Ovarian Cancer Surgical Specimens for TIL-Oriented Cellular Workflows.Cancers · 2026Article
- Single-Cell Transcriptomic Analysis Reveals Ferroptosis-Related Signatures and Tumor Microenvironment Heterogeneity in Epithelial Ovarian Cancer.Cancer medicine · 2026Article
- Multiomics, pharmacogenomic, and structural characterization of NCCRP1 as a candidate therapeutic target in ovarian cancer.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Immunotherapy in Gynecologic Cancers: Current Evidence, Biomarker-Driven Practice, and Future Directions.Cancers · 2026Review
- Cancer drug response and resistance: molecular mechanisms and combating strategies.Signal transduction and targeted therapy · 2026Review
- T Cell-Macrophage Interactions Influence Chemotherapeutic Response in Ovarian Cancer Patients.International journal of molecular sciences · 2026Article
- Upregulation of macrophage UPP1 promotes lung adenocarcinoma metastasis through an mtROS-cGAS-NLRP3 inflammasome axis.Cell death discovery · 2026Article
- An organoid-guided platform for ovarian cancer: enabling prediction of patients' chemotherapy response.Journal of ovarian research · 2026Article
- Single-cell RNA sequencing in ovarian cancer: decoding the tumor microenvironment for personalized therapy.Journal of ovarian research · 2026Review
- Protocol for culture, drug treatment, and dissociation of patient-derived 3D ovarian cancer microspheroids for flow cytometry.STAR protocols · 2026Article
- Ciliated Cells Drive Critical STING-Mediated Tumor Suppression in the Fallopian Tube Epithelium.Cancer research · 2026Article
- STAT1 and STAT3 signaling in ovarian cancer: prognostic biomarkers and therapeutic targets.BMC cancer · 2026Article
- Advanced 3D cancer models for analyzing tumor-immune cell interaction and therapeutic response.Molecular cancer · 2026Review
- Integrated single-cell and bulk transcriptomics reveals STAB1 as a novel therapeutic target for ovarian cancer.Translational oncology · 2026Article
- Single-cell transcriptomics of chicken ovarian cancer identifying immune subsets with prognostic implications.Poultry science · 2026Article
- Development and validation of a macrophage-related prognostic model for overall survival in ovarian cancer via integrated RNA sequencing analysis.Translational cancer research · 2026Article
273 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 7 institutions in 4 countries.
Benjamin Izar *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Itay Tirosh *Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID http://orcid.org/0000-0001-5477-2987
Elizabeth H Stover *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-6578-3216
Isaac WakiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5248-4823
Michael S CuocoKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-2163-5120
Idan AlterDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Christopher RodmanKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Rachel LeesonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Mei-Ju SuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Parin ShahDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Marcin IwanickiChemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ, USA.ORCID http://orcid.org/0000-0001-8375-8447
Sarah R WalkerMolecular, Cellular, and Biomedical Sciences, College of Life Sciences and Agriculture, University of New Hampshire, Durham, NH, USA.
Abhay KanodiaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Johannes C MelmsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Shaolin MeiLaboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Jia-Ren LinLaboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4702-7705
Caroline B M PorterKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Michal SlyperKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Julia WaldmanKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Livnat Jerby-ArnonKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Orr AshenbergKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Titus J BrinkerGerman Cancer Research Center, Heidelberg, Germany.
Caitlin MillsLaboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-2608-4084
Meri RogavaLaboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.
Sébastien VigneauDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Peter K SorgerLaboratory for Systems Pharmacology, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-3364-1838
Levi A GarrawayGenentech, San Francisco, CA, USA.
Panagiotis A KonstantinopoulosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-1032-1479
Joyce F LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ursula MatulonisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bruce E JohnsonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Orit Rozenblatt-RosenKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6313-3570
Asaf RotemDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Aviv RegevKlarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA. aregev@broadinstitute.org.ORCID http://orcid.org/0000-0003-3293-3158
Broad Institute · USDana-Farber Cancer Institute · USHarvard University · USWeizmann Institute of Science · ILGerman Cancer Research Center · DEStevens Institute of Technology · USUniversity of New Hampshire · US
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MATTHEW G. VANDER HEIDEN · 1985 to 2026
$93.9MSystems Pharmacology of Therapeutic and Adverse Responses to ImmuneCheckpoint and Small Molecule DrugsU54CA225088 · NCI · HARVARD MEDICAL SCHOOL · PI SHARPE, ARLENE H. · 2018 to 2022
$10.8MClinical implementation of single cell tumor transcriptome analysisR33CA202820 · NCI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R., JOHNSON, BRUCE E. · 2016 to 2018
$1.3MThe roles of anti-apoptotic proteins BCL-XL and MCL1 in mediating survival of high-grade serous ovarian cancer following drug-induced DNA damageK08CA237871 · NCI · DANA-FARBER CANCER INST · PI STOVER, ELIZABETH HARMON · 2019 to 2023
$921kDissecting mechanisms of immunotherapy resistance in melanoma patientsK08CA222663 · NCI · DANA-FARBER CANCER INST · PI IZAR, BENJAMIN · 2017 to 2021
$827kNCI NIH HHS K08 CA222663NCI NIH HHS K08 CA237871NCI NIH HHS P30 CA014051NCI NIH HHS R33 CA202820NCI NIH HHS U54 CA225088
Abstract
Malignant abdominal fluid (ascites) frequently develops in women with advanced high-grade serous ovarian cancer (HGSOC) and is associated with drug resistance and a poor prognosis
Indexed as
Single-Cell AnalysisAscitesCell Line, TumorCystadenoma, SerousDNA Copy Number VariationsDrug Resistance, NeoplasmFemaleFibroblastsGene Expression Regulation, NeoplasticHeterograftsHumansJanus Kinase 1Neoplasm GradingNeoplasm ProteinsOvarian NeoplasmsPrognosisJanus Kinase 1Neoplasm ProteinsSTAT Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.